ESR1 and breast carcinoma: Following the same analogy, providing docetaxel for estrogen receptor-negative, progesterone receptor-positive breast cancer could be more effective if the chemotherapy is delivered during the luteal phase of the ovarian cycle, when progesterone levels reach a peak at about 20–24 days from the beginning of the menstrual cycle [47].